Beam Therapeutics Deferred Revenue 2011-2026 | BEAM

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Beam Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
6.66 M	109 M	68.7 M	136 M	86.3 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
136 M	6.66 M	81.3 M

Quarterly Deferred Revenue Beam Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
110 M	106 M	85.2 M	109 M	89.3 M	84.9 M	72.1 M	68.7 M	153 M	139 M	143 M	136 M	160 M	140 M	115 M	86.3 M	12.8 M	10 M	-	24 K	24 K	24 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
160 M	24 K	86.7 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	563 K	-	-	$ 866 M	China
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	124 K	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	2.64 M	$ 22.38	0.81 %	$ 3.71 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Galapagos NV GLPG	443 M	$ 28.15	1.04 %	$ 2.69 B	Belgium
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Grifols, S.A. GRFS	30.1 M	$ 8.22	3.92 %	$ 6.83 B	Spain
ImmuCell Corporation ICCC	24.1 K	$ 8.43	-0.12 %	$ 76.1 M	USA
InflaRx N.V. IFRX	15 K	$ 1.97	-0.51 %	$ 152 M	Germany
Incyte Corporation INCY	12.5 M	$ 98.55	-0.55 %	$ 19.2 B	USA
Innoviva INVA	4.27 M	$ 22.97	-0.35 %	$ 1.55 B	USA
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Brainstorm Cell Therapeutics BCLI	2.62 M	-	-2.5 %	$ 5.88 M	USA
BioNTech SE BNTX	300 M	$ 104.02	2.41 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
Jaguar Health JAGX	170 K	$ 7.34	-6.79 %	$ 17.1 M	USA
Applied Genetic Technologies Corporation AGTC	6.3 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	957 K	-	1.93 %	$ 17.4 M	USA
KalVista Pharmaceuticals KALV	11 M	$ 26.68	0.02 %	$ 1.44 B	Britain
Innate Pharma S.A. IPHA	12.5 M	$ 1.45	-2.68 %	$ 235 M	France
Kamada Ltd. KMDA	222 K	$ 8.16	0.68 %	$ 260 M	Israel
Kazia Therapeutics Limited KZIA	138 K	$ 13.58	9.34 %	$ 1.8 B	Australia
Ligand Pharmaceuticals Incorporated LGND	1.28 M	$ 220.06	-2.13 %	$ 4.02 B	USA
AlloVir ALVR	2.66 M	-	4.14 %	$ 49.1 M	USA
Can-Fite BioPharma Ltd. CANF	405 K	$ 2.94	-1.67 %	$ 4.84 M	Israel
Liquidia Corporation LQDA	3.61 M	$ 38.41	0.67 %	$ 3.31 B	USA
Ampio Pharmaceuticals AMPE	85.7 K	-	-11.43 %	$ 502 K	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
Applied Therapeutics APLT	667 K	-	-	$ 8.42 M	USA
Aquestive Therapeutics AQST	1.09 M	$ 4.08	0.62 %	$ 436 M	USA
Aravive ARAV	4.41 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	20.2 M	-	17.91 %	$ 11.1 M	USA